Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Squamous Cell 3Rectal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adenocarcinoma Of Esophagus 2Tonsillar Neoplasms 1Resectable Esophageal Cancer 1Pharyngeal Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle Invasive Bladder Cancer 1Melanoma 1Lung Neoplasms 1Limited Stage Small Cell Lung Cancer 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Radiation 1Paclitaxel 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Resectable Esophageal Cancer × Chemoradiotherapy × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡